25 XP   0   0   10

Fusion Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Fusion Pharmaceuticals Inc together

PenkeI guess you are interested in Fusion Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Fusion Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Fusion Pharmaceuticals Inc

I send you an email if I find something interesting about Fusion Pharmaceuticals Inc.

Quick analysis of Fusion Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Fusion Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
15.0%

What is your share worth?

Current worth
$2.63
Expected worth in 1 year
$3.34
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$0.71
Return On Investment
3.3%

For what price can you sell your share?

Current Price per Share
$21.32
Expected price per share
$9.09 - $21.55
How sure are you?
50%

1. Valuation of Fusion Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$21.32

Intrinsic Value Per Share

$-15.40 - $-18.15

Total Value Per Share

$-12.78 - $-15.52

2. Growth of Fusion Pharmaceuticals Inc (5 min.)




Is Fusion Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$222.4m$189.9m$13.7m6.8%

How much money is Fusion Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$23.7m-$21.9m-$1.8m-7.7%
Net Profit Margin-40,414.4%-9,699.7%--

How much money comes from the company's main activities?

3. Financial Health of Fusion Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#234 / 1011

Most Revenue
#546 / 1011

Most Profit
#724 / 1011

Most Efficient
#983 / 1011

What can you expect buying and holding a share of Fusion Pharmaceuticals Inc? (5 min.)

Welcome investor! Fusion Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Fusion Pharmaceuticals Inc.

What can you expect buying and holding a share of Fusion Pharmaceuticals Inc?

First you should know what it really means to hold a share of Fusion Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Fusion Pharmaceuticals Inc is $21.32. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Fusion Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Fusion Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.63. Based on the TTM, the Book Value Change Per Share is $0.18 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.20 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Fusion Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.33-1.6%-0.28-1.3%-0.26-1.2%-0.22-1.0%-0.22-1.0%
Usd Book Value Change Per Share0.401.9%0.180.8%-0.20-1.0%0.120.5%0.120.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.401.9%0.180.8%-0.20-0.9%0.120.6%0.120.6%
Usd Price Per Share9.61-5.16-4.11-5.46-5.46-
Price to Earnings Ratio-7.22--4.41--4.10--5.97--5.97-
Price-to-Total Gains Ratio23.93-50.72--20.81--18.18--18.18-
Price to Book Ratio3.66-2.09-1.79-1.85-1.85-
Price-to-Total Gains Ratio23.93-50.72--20.81--18.18--18.18-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share21.32
Number of shares46
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.180.12
Usd Total Gains Per Share0.180.12
Gains per Quarter (46 shares)8.185.47
Gains per Year (46 shares)32.7321.89
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10332302212
20655614334
30988916556
4013112228678
501641552108100
601961882129122
702292213151144
802622543172166
902952873194188
1003273204215210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.020.00.00.0%0.020.03.00.0%
Book Value Change Per Share3.01.00.075.0%3.09.00.025.0%5.012.03.025.0%5.012.03.025.0%7.013.03.030.4%
Dividend per Share0.00.04.00.0%1.00.011.08.3%3.00.017.015.0%3.00.017.015.0%3.00.020.013.0%
Total Gains per Share3.01.00.075.0%3.09.00.025.0%5.012.03.025.0%5.012.03.025.0%7.013.03.030.4%

Fundamentals of Fusion Pharmaceuticals Inc

About Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

Fundamental data was last updated by Penke on 2024-04-11 09:32:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Fusion Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Fusion Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Fusion Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Fusion Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-40,414.4%+40,414.4%
TTM-40,414.4%YOY-9,699.7%-30,714.8%
TTM-40,414.4%5Y-10,724.5%-29,689.9%
5Y-10,724.5%10Y-10,724.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.1%+196.1%
TTM-40,414.4%-211.9%-40,202.5%
YOY-9,699.7%-277.7%-9,422.0%
5Y-10,724.5%-432.9%-10,291.6%
10Y-10,724.5%-599.3%-10,125.2%
1.1.2. Return on Assets

Shows how efficient Fusion Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Fusion Pharmaceuticals Inc to the Biotechnology industry mean.
  • -9.9% Return on Assets means that Fusion Pharmaceuticals Inc generated $-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Fusion Pharmaceuticals Inc:

  • The MRQ is -9.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.9%TTM-8.8%-1.1%
TTM-8.8%YOY-9.5%+0.7%
TTM-8.8%5Y-8.9%+0.1%
5Y-8.9%10Y-8.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.9%-13.3%+3.4%
TTM-8.8%-12.7%+3.9%
YOY-9.5%-11.8%+2.3%
5Y-8.9%-14.0%+5.1%
10Y-8.9%-15.9%+7.0%
1.1.3. Return on Equity

Shows how efficient Fusion Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Fusion Pharmaceuticals Inc to the Biotechnology industry mean.
  • -12.7% Return on Equity means Fusion Pharmaceuticals Inc generated $-0.13 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Fusion Pharmaceuticals Inc:

  • The MRQ is -12.7%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -11.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.7%TTM-11.6%-1.1%
TTM-11.6%YOY-11.8%+0.2%
TTM-11.6%5Y-9.9%-1.7%
5Y-9.9%10Y-9.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.7%-16.9%+4.2%
TTM-11.6%-16.0%+4.4%
YOY-11.8%-15.1%+3.3%
5Y-9.9%-19.7%+9.8%
10Y-9.9%-20.5%+10.6%

1.2. Operating Efficiency of Fusion Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Fusion Pharmaceuticals Inc is operating .

  • Measures how much profit Fusion Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Fusion Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Fusion Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-40,186.8%+40,186.8%
TTM-40,186.8%YOY-9,668.3%-30,518.5%
TTM-40,186.8%5Y-10,682.2%-29,504.6%
5Y-10,682.2%10Y-10,682.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--290.9%+290.9%
TTM-40,186.8%-224.4%-39,962.4%
YOY-9,668.3%-288.3%-9,380.0%
5Y-10,682.2%-479.5%-10,202.7%
10Y-10,682.2%-625.2%-10,057.0%
1.2.2. Operating Ratio

Measures how efficient Fusion Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Fusion Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM570.240-570.240
TTM570.240YOY159.347+410.893
TTM570.2405Y153.164+417.076
5Y153.16410Y153.1640.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.110-3.110
TTM570.2403.266+566.974
YOY159.3473.783+155.564
5Y153.1645.657+147.507
10Y153.1647.783+145.381

1.3. Liquidity of Fusion Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Fusion Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 15.01 means the company has $15.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Fusion Pharmaceuticals Inc:

  • The MRQ is 15.006. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.882. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ15.006TTM12.882+2.123
TTM12.882YOY15.668-2.785
TTM12.8825Y16.974-4.092
5Y16.97410Y16.9740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.0063.905+11.101
TTM12.8824.212+8.670
YOY15.6685.337+10.331
5Y16.9746.062+10.912
10Y16.9746.401+10.573
1.3.2. Quick Ratio

Measures if Fusion Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Fusion Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 25.30 means the company can pay off $25.30 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Fusion Pharmaceuticals Inc:

  • The MRQ is 25.305. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 22.295. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ25.305TTM22.295+3.010
TTM22.295YOY25.166-2.872
TTM22.2955Y24.690-2.396
5Y24.69010Y24.6900.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.3053.572+21.733
TTM22.2954.001+18.294
YOY25.1665.364+19.802
5Y24.6906.009+18.681
10Y24.6906.287+18.403

1.4. Solvency of Fusion Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Fusion Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Fusion Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.22 means that Fusion Pharmaceuticals Inc assets are financed with 22.2% credit (debt) and the remaining percentage (100% - 22.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Fusion Pharmaceuticals Inc:

  • The MRQ is 0.222. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.242. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.222TTM0.242-0.020
TTM0.242YOY0.177+0.065
TTM0.2425Y0.211+0.031
5Y0.21110Y0.2110.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2220.336-0.114
TTM0.2420.334-0.092
YOY0.1770.271-0.094
5Y0.2110.366-0.155
10Y0.2110.389-0.178
1.4.2. Debt to Equity Ratio

Measures if Fusion Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Fusion Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 28.5% means that company has $0.28 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Fusion Pharmaceuticals Inc:

  • The MRQ is 0.285. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.320. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.285TTM0.320-0.035
TTM0.320YOY0.224+0.096
TTM0.3205Y0.171+0.149
5Y0.17110Y0.1710.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2850.382-0.097
TTM0.3200.397-0.077
YOY0.2240.341-0.117
5Y0.1710.432-0.261
10Y0.1710.465-0.294

2. Market Valuation of Fusion Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Fusion Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Fusion Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -7.22 means the investor is paying $-7.22 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Fusion Pharmaceuticals Inc:

  • The EOD is -16.019. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.221. Based on the earnings, the company is expensive. -2
  • The TTM is -4.406. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.019MRQ-7.221-8.799
MRQ-7.221TTM-4.406-2.814
TTM-4.406YOY-4.098-0.309
TTM-4.4065Y-5.971+1.564
5Y-5.97110Y-5.9710.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.019-2.262-13.757
MRQ-7.221-2.599-4.622
TTM-4.406-2.674-1.732
YOY-4.098-4.133+0.035
5Y-5.971-6.258+0.287
10Y-5.971-6.171+0.200
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Fusion Pharmaceuticals Inc:

  • The EOD is -24.568. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.074. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.448. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-24.568MRQ-11.074-13.494
MRQ-11.074TTM-5.448-5.626
TTM-5.448YOY-4.937-0.510
TTM-5.4485Y-11.554+6.106
5Y-11.55410Y-11.5540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-24.568-2.913-21.655
MRQ-11.074-3.275-7.799
TTM-5.448-3.508-1.940
YOY-4.937-5.620+0.683
5Y-11.554-8.306-3.248
10Y-11.554-8.854-2.700
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Fusion Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.66 means the investor is paying $3.66 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Fusion Pharmaceuticals Inc:

  • The EOD is 8.116. Based on the equity, the company is overpriced. -1
  • The MRQ is 3.658. Based on the equity, the company is fair priced.
  • The TTM is 2.091. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD8.116MRQ3.658+4.458
MRQ3.658TTM2.091+1.567
TTM2.091YOY1.788+0.303
TTM2.0915Y1.850+0.241
5Y1.85010Y1.8500.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.1161.858+6.258
MRQ3.6582.090+1.568
TTM2.0912.091+0.000
YOY1.7882.866-1.078
5Y1.8503.488-1.638
10Y1.8503.836-1.986
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Fusion Pharmaceuticals Inc.

3.1. Institutions holding Fusion Pharmaceuticals Inc

Institutions are holding 79.032% of the shares of Fusion Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Federated Hermes Inc12.85370.2597108861532023641.8941
2023-12-31Avidity Partners Management LP7.67522.2766650032871847812.4264
2023-12-31FMR Inc6.27360.00395313294113544627.1778
2023-12-31Johnson & Johnson4.33390.8042367051600
2023-12-31Orbimed Advisors, LLC3.68720.5993312277000
2023-12-31Canada Pension Plan Investment Board3.68030.0378311696600
2023-12-31Adams Street Partners LLC3.48068.7281294780900
2023-09-30Deerfield Management Co3.33320.1617282300000
2023-12-31Perceptive Advisors LLC3.24870.5902275139500
2023-12-31TPG GP A, LLC3.0130.3955255179400
2023-12-31Pivotal bioVenture Partners Investment Advisor LLC1.84313.8053156098200
2023-12-31Sphera Funds Management Ltd.1.28191.67911085639-268619-19.8351
2023-12-31Artal Group S A1.18720.32121005500-719500-41.7101
2023-12-31Blair William & Co1.17350.03269938559938550
2023-12-31Wellington Management Company LLP0.8790.00137444747444740
2023-12-311832 Asset Management L.P0.8670.010273432100
2023-12-31Eagle Health Investments LP0.68461.132157976900
2023-12-31Millennium Management LLC0.68260.0024578102-4027-0.6918
2023-12-31Ikarian Capital, LLC0.59040.44995000005000000
2023-12-31BlackRock Inc0.49570.00014198064115534986.7079
Total 61.264421.291251886473+3714024+7.2%

3.2. Funds holding Fusion Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Federated Hermes Kaufmann Growth6.47051.079954800111500112.8145
2023-12-31Federated Hermes Kaufmann R6.47051.079954800111500112.8145
2023-12-31Federated Hermes Kaufmann Small Cap Grow5.99141.159550742311286312.6009
2023-12-31Federated Hermes Kaufmann Small Cap A5.99141.159550742311286312.6009
2024-01-31Fidelity Small Cap Growth2.05860.35341743477-2104-0.1205
2024-02-29Fidelity Select Biotechnology1.47370.30361248102-255000-16.9649
2024-02-29Fidelity Advisor Biotechnology I1.36060.775115231000
2024-02-29Wellington Global Hlthcr Eq USD G Ac1.02610.39558690258690250
2024-01-31Fidelity Small Cap Growth K60.73010.336361832321040.3414
2024-03-28iShares Biotechnology ETF0.48910.11574142036077817.1969
2024-02-29Hartford Healthcare Y0.38180.32883233503233500
2024-02-29Nationwide International Sm Cp R60.29450.47072494488671553.2867
2024-02-29Franklin Biotechnology Discv A(acc)USD0.24190.13282048622396213.246
2024-02-29Hartford Small Company Y0.20220.31321712711712710
2024-01-31Alger Small Cap Growth B0.1950.633616517500
2023-12-31Federated Hermes Kaufmann II P0.19121.259416191137222.3529
2024-02-29Lord Abbett Micro Cap Growth I0.18380.96915566500
2023-12-31Federated Hermes Intl Small-Mid Co A0.17710.596115000000
2023-12-31Federated Hermes Non-U.S. Small /Mid Cap0.17710.594815000000
2023-12-31Vanguard International Explorer Inv0.16230.08881374221374220
Total 34.268912.145529023028+1978529+6.8%

3.3. Insider Transactions

Insiders are holding 4.406% of the shares of Fusion Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-08-11Steven GannonBUY444002.03
2022-04-27John ValliantSELL45116.03
2022-04-25John ValliantSELL20366.03
2022-04-20John ValliantSELL3676.02
2022-04-13John ValliantSELL119946.41
2022-04-11John ValliantSELL26007.37
2022-04-08John ValliantSELL8267.52
2022-04-06John ValliantSELL1007.58
2022-03-30John ValliantSELL3007.52
2022-03-28John ValliantSELL96007.55
2022-03-25John ValliantSELL5007.42
2022-03-23John ValliantSELL1007.5
2022-03-21John ValliantSELL15007.47
2022-03-17John ValliantSELL9007.51
2022-03-07John ValliantSELL31006.99
2022-03-04John ValliantSELL84007.32
2022-02-28John ValliantSELL31007.4
2022-02-24John ValliantSELL25007.41
2022-02-22John ValliantSELL41007.85
2022-02-17John ValliantSELL17007.98

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Fusion Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4020.178+126%-0.204+151%0.117+244%0.117+244%
Book Value Per Share--2.6272.405+9%2.243+17%2.131+23%2.131+23%
Current Ratio--15.00612.882+16%15.668-4%16.974-12%16.974-12%
Debt To Asset Ratio--0.2220.242-8%0.177+25%0.211+5%0.211+5%
Debt To Equity Ratio--0.2850.320-11%0.224+27%0.171+67%0.171+67%
Dividend Per Share----0%0.002-100%0.002-100%0.002-100%
Eps---0.333-0.280-16%-0.259-22%-0.217-35%-0.217-35%
Free Cash Flow Per Share---0.217-0.250+15%-0.223+3%-0.167-23%-0.167-23%
Free Cash Flow To Equity Per Share--0.4470.165+172%-0.102+123%0.128+249%0.128+249%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---18.148--------
Intrinsic Value_10Y_min---15.402--------
Intrinsic Value_1Y_max---1.063--------
Intrinsic Value_1Y_min---1.044--------
Intrinsic Value_3Y_max---3.771--------
Intrinsic Value_3Y_min---3.588--------
Intrinsic Value_5Y_max---7.172--------
Intrinsic Value_5Y_min---6.607--------
Market Cap1805646232.000+55%813895886.000437225547.500+86%347663123.000+134%462421596.000+76%462421596.000+76%
Net Profit Margin----404.1440%-96.9970%-107.2450%-107.2450%
Operating Margin----401.8680%-96.6830%-106.8220%-106.8220%
Operating Ratio---570.240-100%159.347-100%153.164-100%153.164-100%
Pb Ratio8.116+55%3.6582.091+75%1.788+105%1.850+98%1.850+98%
Pe Ratio-16.019-122%-7.221-4.406-39%-4.098-43%-5.971-17%-5.971-17%
Price Per Share21.320+55%9.6105.163+86%4.105+134%5.460+76%5.460+76%
Price To Free Cash Flow Ratio-24.568-122%-11.074-5.448-51%-4.937-55%-11.554+4%-11.554+4%
Price To Total Gains Ratio53.093+55%23.93250.717-53%-20.814+187%-18.179+176%-18.179+176%
Quick Ratio--25.30522.295+14%25.166+1%24.690+2%24.690+2%
Return On Assets---0.099-0.088-11%-0.095-3%-0.089-10%-0.089-10%
Return On Equity---0.127-0.116-9%-0.118-7%-0.099-22%-0.099-22%
Total Gains Per Share--0.4020.178+126%-0.202+150%0.119+237%0.119+237%
Usd Book Value--222480000.000203686250.000+9%189924000.000+17%180479400.000+23%180479400.000+23%
Usd Book Value Change Per Share--0.4020.178+126%-0.204+151%0.117+244%0.117+244%
Usd Book Value Per Share--2.6272.405+9%2.243+17%2.131+23%2.131+23%
Usd Dividend Per Share----0%0.002-100%0.002-100%0.002-100%
Usd Eps---0.333-0.280-16%-0.259-22%-0.217-35%-0.217-35%
Usd Free Cash Flow---18373866.000-21159466.500+15%-18854500.000+3%-14116143.300-23%-14116143.300-23%
Usd Free Cash Flow Per Share---0.217-0.250+15%-0.223+3%-0.167-23%-0.167-23%
Usd Free Cash Flow To Equity Per Share--0.4470.165+172%-0.102+123%0.128+249%0.128+249%
Usd Market Cap1805646232.000+55%813895886.000437225547.500+86%347663123.000+134%462421596.000+76%462421596.000+76%
Usd Price Per Share21.320+55%9.6105.163+86%4.105+134%5.460+76%5.460+76%
Usd Profit---28179000.000-23724250.000-16%-21903000.000-22%-17903900.000-36%-17903900.000-36%
Usd Revenue---517000.000-100%365250.000-100%248450.000-100%248450.000-100%
Usd Total Gains Per Share--0.4020.178+126%-0.202+150%0.119+237%0.119+237%
 EOD+6 -2MRQTTM+22 -9YOY+20 -135Y+16 -1710Y+16 -17

4.2. Fundamental Score

Let's check the fundamental score of Fusion Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-16.019
Price to Book Ratio (EOD)Between0-18.116
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than125.305
Current Ratio (MRQ)Greater than115.006
Debt to Asset Ratio (MRQ)Less than10.222
Debt to Equity Ratio (MRQ)Less than10.285
Return on Equity (MRQ)Greater than0.15-0.127
Return on Assets (MRQ)Greater than0.05-0.099
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Fusion Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5079.885
Ma 20Greater thanMa 5021.308
Ma 50Greater thanMa 10016.053
Ma 100Greater thanMa 20012.121
OpenGreater thanClose21.260
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -469384-85-167-252-589-8411,078237
Tax Provision  -340329-11-234-245-8-2531,5491,296
Income Tax Expense  -340329-11-234-245-8-2531,5491,296



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets285,836
Total Liabilities63,356
Total Stockholder Equity222,480
 As reported
Total Liabilities 63,356
Total Stockholder Equity+ 222,480
Total Assets = 285,836

Assets

Total Assets285,836
Total Current Assets243,395
Long-term Assets42,441
Total Current Assets
Cash And Cash Equivalents 61,925
Short-term Investments 172,153
Net Receivables 4,215
Other Current Assets 5,102
Total Current Assets  (as reported)243,395
Total Current Assets  (calculated)243,395
+/-0
Long-term Assets
Property Plant Equipment 23,896
Long Term Investments 13,735
Long-term Assets Other 849
Long-term Assets  (as reported)42,441
Long-term Assets  (calculated)38,480
+/- 3,961

Liabilities & Shareholders' Equity

Total Current Liabilities16,220
Long-term Liabilities47,136
Total Stockholder Equity222,480
Total Current Liabilities
Short-term Debt 4,163
Accounts payable 1,860
Other Current Liabilities 9,864
Total Current Liabilities  (as reported)16,220
Total Current Liabilities  (calculated)15,887
+/- 333
Long-term Liabilities
Long term Debt 34,775
Capital Lease Obligations Min Short Term Debt11,393
Long-term Liabilities  (as reported)47,136
Long-term Liabilities  (calculated)46,168
+/- 968
Total Stockholder Equity
Retained Earnings -376,759
Accumulated Other Comprehensive Income 237
Other Stockholders Equity 599,002
Total Stockholder Equity (as reported)222,480
Total Stockholder Equity (calculated)222,480
+/-0
Other
Cash and Short Term Investments 234,078
Common Stock Shares Outstanding 73,094
Current Deferred Revenue333
Liabilities and Stockholders Equity 285,836
Net Debt -11,594
Net Invested Capital 257,255
Net Working Capital 227,175
Property Plant and Equipment Gross 26,352
Short Long Term Debt Total 50,331



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312000-09-302000-06-302000-03-31
> Total Assets 
13,104
43,024
29,163
0
0
0
69,400
73,389
323,110
312,059
310,676
297,308
282,156
268,303
252,271
235,960
228,135
238,493
219,064
266,551
268,286
253,377
285,836
285,836253,377268,286266,551219,064238,493228,135235,960252,271268,303282,156297,308310,676312,059323,11073,38969,40000029,16343,02413,104
   > Total Current Assets 
0
0
0
0
0
0
66,553
68,740
320,132
296,884
228,164
233,855
185,156
203,009
211,762
204,777
207,075
215,846
178,998
220,624
207,860
203,265
243,395
243,395203,265207,860220,624178,998215,846207,075204,777211,762203,009185,156233,855228,164296,884320,13268,74066,553000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
65,344
67,417
318,892
248,793
90,517
41,070
27,615
38,379
52,898
59,211
61,524
106,052
43,861
53,617
32,022
26,787
61,925
61,92526,78732,02253,61743,861106,05261,52459,21152,89838,37927,61541,07090,517248,793318,89267,41765,344000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
43,159
131,882
186,150
150,904
154,238
147,897
137,601
136,899
99,429
127,013
156,227
166,074
164,561
172,153
172,153164,561166,074156,227127,01399,429136,899137,601147,897154,238150,904186,150131,88243,159000000000
       Net Receivables 
0
0
0
0
0
0
428
693
411
891
794
979
1,351
2,285
357
1,693
2,602
2,922
1,723
2,541
2,402
2,367
4,215
4,2152,3672,4022,5411,7232,9222,6021,6933572,2851,351979794891411693428000000
       Inventory 
0
0
0
0
0
0
503
433
453
3,589
4,244
5,178
5,059
7,796
10,377
5,850
5,510
6,808
-9,869
-4,396
5,667
8,229
0
08,2295,667-4,396-9,8696,8085,5105,85010,3777,7965,0595,1784,2443,589453433503000000
   > Long-term Assets 
0
0
0
0
0
0
2,847
4,649
2,978
15,175
82,512
63,453
97,000
65,294
40,509
31,183
21,060
22,647
40,066
45,927
60,426
50,112
42,441
42,44150,11260,42645,92740,06622,64721,06031,18340,50965,29497,00063,45382,51215,1752,9784,6492,847000000
       Property Plant Equipment 
1,815
3,274
1,691
0
0
0
1,272
1,334
1,403
1,981
1,967
10,060
9,883
9,406
9,453
9,942
9,765
9,823
10,315
22,981
23,341
24,981
23,896
23,89624,98123,34122,98110,3159,8239,7659,9429,4539,4069,88310,0601,9671,9811,4031,3341,2720001,6913,2741,815
       Long Term Investments 
0
0
0
0
0
0
0
0
0
11,102
77,082
50,997
81,974
45,554
19,987
9,901
0
0
15,761
11,338
28,423
15,931
13,735
13,73515,93128,42311,33815,761009,90119,98745,55481,97450,99777,08211,102000000000
       Long-term Assets Other 
0
0
0
0
0
0
1,497
3,237
1,497
1,986
2,810
1,743
4,076
9,010
9,424
9,355
9,058
8,669
9,184
6,308
2,666
2,322
849
8492,3222,6666,3089,1848,6699,0589,3559,4249,0104,0761,7432,8101,9861,4973,2371,497000000
> Total Liabilities 
10,338
14,898
4,646
0
0
0
102,888
15,052
7,903
5,605
16,163
18,237
18,605
21,808
20,815
20,534
29,228
55,351
56,843
65,718
65,325
64,906
63,356
63,35664,90665,32565,71856,84355,35129,22820,53420,81521,80818,60518,23716,1635,6057,90315,052102,8880004,64614,89810,338
   > Total Current Liabilities 
10,323
10,882
647
0
0
0
4,273
6,795
7,610
5,309
11,857
7,618
9,365
13,563
12,511
12,182
11,576
13,412
15,067
17,325
17,094
17,478
16,220
16,22017,47817,09417,32515,06713,41211,57612,18212,51113,5639,3657,61811,8575,3097,6106,7954,27300064710,88210,323
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
2,799
1,194
1,265
1,327
1,215
1,434
1,437
1,431
1,443
4,638
5,357
6,166
4,163
4,1636,1665,3574,6381,4431,4311,4371,4341,2151,3271,2651,1942,7990000000000
       Accounts payable 
8,760
9,638
647
0
0
0
830
2,890
703
956
3,399
1,018
685
3,803
2,195
1,774
1,551
1,311
2,686
1,904
2,061
1,057
1,860
1,8601,0572,0611,9042,6861,3111,5511,7742,1953,8036851,0183,3999567032,8908300006479,6388,760
       Other Current Liabilities 
1,549
1,231
0
0
0
0
3,443
3,905
6,907
4,353
4,659
4,406
5,682
6,146
7,563
7,874
7,881
10,258
10,014
10,015
8,907
9,528
9,864
9,8649,5288,90710,01510,01410,2587,8817,8747,5636,1465,6824,4064,6594,3536,9073,9053,44300001,2311,549
   > Long-term Liabilities 
0
0
0
0
0
0
98,615
8,257
293
296
4,306
10,619
9,240
8,245
8,304
8,352
17,652
41,939
41,776
48,393
48,231
47,428
47,136
47,13647,42848,23148,39341,77641,93917,6528,3528,3048,2459,24010,6194,3062962938,25798,615000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,629
34,106
34,233
34,360
0
0
0
00034,36034,23334,1069,6290000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
293
293
296
4,306
4,295
3,162
2,462
2,797
2,797
2,797
2,964
2,966
0
2,966
966
0
09662,96602,9662,9642,7972,7972,7972,4623,1624,2954,3062962932930000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
1,740
0
0
4,011
4,000
2,867
2,167
2,500
2,500
2,500
2,667
2,667
2,667
100
100
0
01001002,6672,6672,6672,5002,5002,5002,1672,8674,0004,011001,7400000000
> Total Stockholder Equity
2,766
28,126
24,517
0
0
0
-33,488
58,337
315,207
306,454
294,513
279,071
263,551
246,495
231,456
215,426
198,907
183,142
162,221
200,833
202,961
188,471
222,480
222,480188,471202,961200,833162,221183,142198,907215,426231,456246,495263,551279,071294,513306,454315,20758,337-33,48800024,51728,1262,766
   Common Stock
39
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000039
   Retained Earnings Total Equity000-306,153-281,862-257,245-233,232-214,159-194,250-177,014-157,585-130,732-113,2030000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-428
0
0
-1
44
283
337
63
-115
-578
-1,060
-1,256
-469
-85
-252
-841
237
237-841-252-85-469-1,256-1,060-578-1156333728344-100-428000000
   Capital Surplus 
0
0
0
0
0
0
0
358
0
0
407,672
409,520
420,799
423,446
425,821
430,163
433,199
441,643
444,552
507,071
0
0
0
000507,071444,552441,643433,199430,163425,821423,446420,799409,520407,672003580000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
1,714
103,429
405,032
406,273
407,672
409,520
420,799
423,446
425,821
430,163
433,199
441,643
444,552
507,071
534,541
537,892
599,002
599,002537,892534,541507,071444,552441,643433,199430,163425,821423,446420,799409,520407,672406,273405,032103,4291,714000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue2,068
Cost of Revenue-1,345
Gross Profit723723
 
Operating Income (+$)
Gross Profit723
Operating Expense-99,955
Operating Income-99,232-99,232
 
Operating Expense (+$)
Research Development68,758
Selling General Administrative31,197
Selling And Marketing Expenses0
Operating Expense99,95599,955
 
Net Interest Income (+$)
Interest Income8,542
Interest Expense-5,166
Other Finance Cost-168
Net Interest Income3,544
 
Pretax Income (+$)
Operating Income-99,232
Net Interest Income3,544
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-94,110-104,354
EBIT - interestExpense = -104,398
-94,110
-89,731
Interest Expense5,166
Earnings Before Interest and Taxes (EBIT)-99,232-88,944
Earnings Before Interest and Taxes (EBITDA)-97,887
 
After tax Income (+$)
Income Before Tax-94,110
Tax Provision--849
Net Income From Continuing Ops-91,335-93,261
Net Income-94,897
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses101,300
Total Other Income/Expenses Net5,122-3,544
 

Technical Analysis of Fusion Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Fusion Pharmaceuticals Inc. The general trend of Fusion Pharmaceuticals Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Fusion Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Fusion Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 21.44 < 21.55.

The bearish price targets are: 20.97 > 13.99 > 9.09.

Tweet this
Fusion Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Fusion Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Fusion Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Fusion Pharmaceuticals Inc. The current macd is 1.48323193.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Fusion Pharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Fusion Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Fusion Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Fusion Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartFusion Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Fusion Pharmaceuticals Inc. The current adx is 58.58.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Fusion Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Fusion Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Fusion Pharmaceuticals Inc. The current sar is 18.84.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Fusion Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Fusion Pharmaceuticals Inc. The current rsi is 79.88. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
Fusion Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartFusion Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Fusion Pharmaceuticals Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Fusion Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Fusion Pharmaceuticals Inc Daily Stochastic Oscillator ChartFusion Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Fusion Pharmaceuticals Inc. The current cci is -0.07881463.

Fusion Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartFusion Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Fusion Pharmaceuticals Inc. The current cmo is 61.50.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Fusion Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartFusion Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Fusion Pharmaceuticals Inc. The current willr is -39.65517241.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Fusion Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Fusion Pharmaceuticals Inc Daily Williams %R ChartFusion Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Fusion Pharmaceuticals Inc.

Fusion Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Fusion Pharmaceuticals Inc. The current atr is 0.39370565.

Fusion Pharmaceuticals Inc Daily Average True Range (ATR) ChartFusion Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Fusion Pharmaceuticals Inc. The current obv is 70,112,511.

Fusion Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartFusion Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Fusion Pharmaceuticals Inc. The current mfi is 49.52.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Fusion Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartFusion Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Fusion Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-24MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-01RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-10MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Fusion Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Fusion Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5079.885
Ma 20Greater thanMa 5021.308
Ma 50Greater thanMa 10016.053
Ma 100Greater thanMa 20012.121
OpenGreater thanClose21.260
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Fusion Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Fusion Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Fusion Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Fusion Pharmaceuticals Inc

I send you an email if I find something interesting about Fusion Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Fusion Pharmaceuticals Inc.

Receive notifications about Fusion Pharmaceuticals Inc in your mailbox!